Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harvard Bioscience (HBIO) Accumulated Expenses (2016 - 2025)

Historic Accumulated Expenses for Harvard Bioscience (HBIO) over the last 17 years, with Q3 2025 value amounting to $1.9 million.

  • Harvard Bioscience's Accumulated Expenses rose 80.82% to $1.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.9 million, marking a year-over-year increase of 80.82%. This contributed to the annual value of $1.7 million for FY2024, which is 5637.57% down from last year.
  • Latest data reveals that Harvard Bioscience reported Accumulated Expenses of $1.9 million as of Q3 2025, which was up 80.82% from $2.1 million recorded in Q2 2025.
  • In the past 5 years, Harvard Bioscience's Accumulated Expenses ranged from a high of $6.0 million in Q4 2021 and a low of $1.7 million during Q4 2024
  • For the 5-year period, Harvard Bioscience's Accumulated Expenses averaged around $3.1 million, with its median value being $3.1 million (2022).
  • Per our database at Business Quant, Harvard Bioscience's Accumulated Expenses soared by 7998.2% in 2021 and then tumbled by 5637.57% in 2024.
  • Quarter analysis of 5 years shows Harvard Bioscience's Accumulated Expenses stood at $6.0 million in 2021, then tumbled by 42.53% to $3.5 million in 2022, then grew by 13.03% to $3.9 million in 2023, then crashed by 56.38% to $1.7 million in 2024, then rose by 9.16% to $1.9 million in 2025.
  • Its last three reported values are $1.9 million in Q3 2025, $2.1 million for Q2 2025, and $1.9 million during Q1 2025.